Loading...
•
Jun 30, 2022
Replimune Q1 2023 Earnings Report
Replimune reported financial results for the fiscal first quarter ended June 30, 2022, and provided a business update.
Key Takeaways
Replimune announced that the target enrollment of 180 patients was reached in the CERPASS trial and the first 75 patients were enrolled in the IGNYTE clinical trial. They also believe that existing cash, cash equivalents and short-term investments will fund operating expenses and capital expenditure requirements into the second half of 2024.
Target enrollment of 180 patients reached in the CERPASS randomized controlled registration-directed clinical trial evaluating RP1 in cutaneous squamous cell carcinoma (CSCC).
First 75 patients enrolled in the IGNYTE clinical trial cohort of RP1 combined with Opdivo® (nivolumab) in anti-PD1 failed melanoma.
RP2/3 update to be provided by year end, including detailed Phase 2 development plans
Existing cash, cash equivalents and short-term investments will fund operating expenses and capital expenditure requirements into the second half of 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...